In naïve samples, PD1 expression was lower in the pCR group than in the non-pCR group (Fig. 7B), suggesting that the non-pCR naïve group had a “colder” tumor immune environment, which accounted for their relatively low response to combination therapy. The gene discussed is PDCD1; the disease is neoplasm.